Advertisement

Annals of Surgical Oncology

, Volume 22, Issue 9, pp 2958–2964 | Cite as

Extent of Colorectal Peritoneal Carcinomatosis: Attempt to Define a Threshold Above Which HIPEC Does Not Offer Survival Benefit: A Comparative Study

  • Diane GoéréEmail author
  • Amine Souadka
  • Matthieu Faron
  • Alexis S. Cloutier
  • Benjamin Viana
  • Charles Honoré
  • Frédéric Dumont
  • Dominique Elias
Gastrointestinal Oncology

Abstract

Background

The main prognostic factors after complete cytoreductive surgery (CCRS) of colorectal peritoneal carcinomatosis (PC) followed by intraperitoneal chemotherapy (IPC) are completeness of the resection and extent of the disease. This study aimed to determine a threshold value above which CCRS plus IPC may not offer survival benefit compared with systemic chemotherapy.

Methods

Between March 2000 and May 2010, 180 patients underwent surgery for PC from colorectal cancer with intended performance of CCRS plus IPC.

Results

Among the 180 patients, CCRS plus IPC could be performed for 139 patients (curative group, 77 %), whereas it could not be performed for 41 patients (palliative group, 23 %). The two groups were comparable in terms of age, gender, primary tumor characteristics, and pre- and postoperative systemic chemotherapy. The mean peritoneal cancer index (PCI) was lower in the curative group (11 ± 7) than in the palliative group (23 ± 7) (p < 0.0001). After a median follow-up period of 60 months (range 47–74 months), the 3-year overall survival (OS) rate was 52 % [95 % confidence interval (CI) 43–61 %] in the curative group compared with 7 % (95 % CI 2–25 %) in the palliative group. Comparison of the survivals for each PCI (ranging from 5 to 36) shows that OS did not differ significantly between the two groups of patients when the PCI was higher than 17 (hazard ratio 0.64; range 0.38–1.09).

Conclusion

This study confirmed the major prognostic impact of PC extent. When the PCI exceeds 17 in PC of colorectal origin, CCRS plus IPC does not seem to offer any survival benefit.

Keywords

Overall Survival Peritoneal Carcinomatosis Curative Group Peritoneal Cancer Index Complete Cytoreduction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Supplementary material

10434_2015_4387_MOESM1_ESM.eps (613 kb)
Overall survival curves according to the extent of peritoneal carcinomatosis (PCI) and the possibility of performing complete cytoreductive surgery plus intraperitoneal chemotherapy (curative group = red, blue, green, purple, and orange curves; palliative group = brown curve). When the PCI was higher than 20, the median overall survival did not differ significantly between the two groups. Supplementary material 1 (EPS 613 kb)

References

  1. 1.
    Jayne DG, Fook S, Loi C, et al. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89:545–50.Google Scholar
  2. 2.
    Sugarbaker PH, Gianola FJ, Speyer JC, et al. Prospective, randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer. Surgery. 1985;98:414–22.PubMedGoogle Scholar
  3. 3.
    Verwaal VC, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis from colorectal cancer. J Clin Oncol 2003;21:3737–43.PubMedCrossRefGoogle Scholar
  4. 4.
    Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with intraperitoneal chemotherapy for management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22:3284–92.PubMedCrossRefGoogle Scholar
  5. 5.
    Esquivel J, Elias D, Baratti D, et al. Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination. J Surg Oncol. 2008;98:263–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Elias D, Lefèvre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27:681–5.PubMedCrossRefGoogle Scholar
  7. 7.
    Yan TD, Morris DL. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for isolated colorectal peritoneal carcinomatosis: experimental therapy or standard of care? Ann Surg. 2008;248:829–35.PubMedGoogle Scholar
  8. 8.
    Verwaal VJ, Bruin S, Boot H, et al. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15:2426–32.PubMedCrossRefGoogle Scholar
  9. 9.
    Elias D, Glehen O, Pocard M, et al. A comparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel, and nonpseudomyxoma appendix. Ann Surg. 2010;251:896–901.PubMedCrossRefGoogle Scholar
  10. 10.
    Goéré D, Malka D, Tzanis D, et al. Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? Ann Surg. 2013;257:1065–71.PubMedCrossRefGoogle Scholar
  11. 11.
    Verwaal VJ, van Tinteren H, van Ruth S, et al. Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. Br J Surg. 2004;91:739–4.CrossRefGoogle Scholar
  12. 12.
    Yan T, Sim J, Morris DL. Selection of patients with colorectal peritoneal carcinomatosis for cytoreductive surgery and perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2007;14:1807–17.PubMedCrossRefGoogle Scholar
  13. 13.
    Franko J, Ibrahim Z, Gusani NJ, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer. 2010;116:3756–62.PubMedCrossRefGoogle Scholar
  14. 14.
    Hompes D, Boot H, van Tinteren H, et al. Unresectable peritoneal carcinomatosis from colorectal cancer: a single-center experience. J Surg Oncol. 2011;104:269–73.PubMedCrossRefGoogle Scholar
  15. 15.
    Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from nongynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88:358–63.PubMedCrossRefGoogle Scholar
  16. 16.
    Franko J, Shi Q, Goldman CD. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2012;30:263–7.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Jacquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res. 1996;15:49–58.Google Scholar
  18. 18.
    Elias D, Blot F, El Otmany A, et al. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer. 2001;92:71–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Gomes da Silva RG, Sugarbaker PH. Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. J Am Coll Surg. 2006;203:878–86.CrossRefGoogle Scholar
  20. 20.
    Cao C, Yan TD, Black D, Morris DL. A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2009;16:2152–65.PubMedCrossRefGoogle Scholar
  21. 21.
    Esquivel J, Sticca R, Sugarbaker P, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol. 2007;14:128–33.Google Scholar
  22. 22.
    Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28:63–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Cotte E, Passot G, Gilly FN, et al. Selection of patients and staging of peritoneal surface malignancies. World J Gastrointest Oncol. 2010;2:31–5.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Cashin PH, Graf W, Nygren P, et al. Patient selection for cytoreductive surgery in colorectal peritoneal carcinomatosis using serum tumor markers: an observational cohort study. Ann Surg. 2012;256:1078–83.PubMedCrossRefGoogle Scholar
  25. 25.
    Passot G, Vaudoyer D, Cotte E, et al. Progression following neoadjuvant systemic chemotherapy may not be a contraindication to a curative approach for colorectal carcinomatosis. Ann Surg. 2012;256:125–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Sanoff HK, Sargent DJ, Campbell ME, et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol. 2008;26:5721–7.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Elias D, Souadka A, Fayard F, et al. Variation in the peritoneal cancer index scores between surgeons and according to when they are determined (before or after cytoreductive surgery). Eur J Surg Oncol. 2012;38:503–8.PubMedCrossRefGoogle Scholar
  28. 28.
    de Bree E, Koops W, Kröger R, et al. Preoperative computed tomography and selection of patients with colorectal peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol. 2006;32:65–71.PubMedCrossRefGoogle Scholar
  29. 29.
    Dromain C, Leboulleux S, Auperin A, et al. Staging of peritoneal carcinomatosis: enhanced CT vs PET/CT. Abdom Imaging. 2008;33:87–93.PubMedCrossRefGoogle Scholar
  30. 30.
    Swellengrebel HA, Zoetmulder FA, Smeenk RM, et al. Quantitative intraoperative assessment of peritoneal carcinomatosis: a comparison of three prognostic tools. Eur J Surg Oncol. 2009;35:1078–84.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2015

Authors and Affiliations

  • Diane Goéré
    • 1
    Email author
  • Amine Souadka
    • 1
  • Matthieu Faron
    • 1
    • 2
  • Alexis S. Cloutier
    • 1
  • Benjamin Viana
    • 1
  • Charles Honoré
    • 1
  • Frédéric Dumont
    • 1
  • Dominique Elias
    • 1
  1. 1.Department of Surgical OncologyGustave Roussy, Cancer CenterVillejuif CedexFrance
  2. 2.Departement of BiostatisticsGustave Roussy, Cancer CenterVillejuif CedexFrance

Personalised recommendations